With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.
(e) Synthesis of BRI7160 and BRI7161; The compounds were prepared according to Reaction Scheme 4: Compound 4 was prepared following the method of R. Guilard et al., Bull. Soc. Chim. Fr., 1996, 133, 65-73.A magnetically stirred suspension of compound 4 (430 mg, 0.86 mmol), (4-bromomethyl) methyl benzoate (217 mg, 0.95 mmol), KHCO3 (172 mg) and K2CO3 (174 mg) in dry acetonitrile (17 ml) was heated at reflux for 18 h under an atmosphere of nitrogen. The reaction mixture was cooled to room temperature then concentrated under reduced pressure to yield a straw coloured oil which was purified by flash chromatography (silica, 5% methanol/dichloromethane elution). Concentration of the appropriate fractions (RF 0.38) afforded adduct 5a as a clear, colourless oil. Mass Spectrum (APCI) m/z 649 [(M+H)+, 100%]., 170161-27-0
As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.
Reference£º
Patent; Prana Biotechnology Ltd; US7704987; (2010); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI